ArticleBMC infectious diseases2026
Prevalence and kinetics of viral infections during the first 100 days after pediatric hematopoietic stem cell transplantation at the Children's Hospital in Rabat.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundViral infections are a major cause of morbidity and mortality in pediatric patients undergoing hematopoietic stem cell transplantation (HSCT), particularly during the first 100 days post-transplant, a period of profound immunosuppression. Data on their prevalence and kinetics in low- and middle-income countries, including Morocco, remain limited. This study aimed to evaluate these infections at the Children's Hospital in Rabat.
methodsWe conducted a retrospective descriptive study of pediatric patients who underwent HSCT at the Children's Hospital in Rabat from January 2018 to June 2025. Post-transplant viral monitoring included weekly quantitative PCR for cytomegalovirus (CMV) and Epstein-Barr virus (EBV) until day 100. Targeted PCR for adenovirus, BK virus, HHV-6, and respiratory viruses was performed in symptomatic patients.
resultsOut of 33 patients, CMV was the most frequently detected agent, with an incidence of 51,5% (n = 17), of which 30.3% had a viral load > 2.5 log₁₀ IU/ml. The median time to first reactivation was 3 weeks (IQR: 2-6). The vast majority of episodes occurred in seropositive (R+) recipients, mainly D+/R+. The highest viral loads were observed in patients with CMV viremia temporally associated with pulmonary involvement (2.62 log₁₀ IU/ml [IQR: 0.00-3.42]) compared to those without pulmonary involvement (0.00 log₁₀ IU/ml [IQR: 0.00-2.04]; p = 0.007), despite the absence of virological confirmation of CMV-related pulmonary disease. Similarly, patients with gastrointestinal (GI) complications had higher viral loads (3.13 log₁₀ IU/ml [IQR: 2.23-3.89]) compared with those without GI involvement (0.00 log₁₀ IU/ml [IQR: 0.00-2.04], p = 0.002). Concerning EBV, viral loads showed transient reactivations, fluctuating between quantifiable and undetectable, mainly between the 1st and 7th week post-transplant. Infections were more frequent in recipients who were initially seronegative (D+/R-) included 8 of 13 patients (61.5%), No cases of post-transplant lymphoproliferative disease were reported. BK virus showed an early peak of infection between the 1st and 4th week, strongly associated with the occurrence of hemorrhagic cystitis, highlighting its significant clinical impact during this period.
conclusionThis study highlights the particularly early kinetics of CMV, BK virus, and EBV in our pediatric patients after HSCT, with CMV appearing around week 3, transient EBV reactivations in initially seronegative patients, and an early BK virus peak linked to hemorrhagic cystitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.